Study design
This phase 2a study consisted of a 12-week, double-blind, placebo-controlled treatment period in which patients received intravenous (IV) brazikumab 700 mg or placebo on days 1 and 29, a 100-week, open-label treatment period in which all patients received subcutaneous (SC) brazikumab 210 mg every 4 weeks (maximum of 26 dose administrations), and a 36-week, post-treatment follow-up period (Fig. Study design. BRZ, brazikumab; IV, intravenous; OL, open-label; PBO, placebo; SC, subcutaneous